SCHEMBL6730475

SCHEMBL6730475

Cc1csc(-c2noc(C(F)F)c2-c2ccc(S(C)(=O)=O)c(F)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CB P42338 2/20 0.37
PIK3CG P48736 2/20 0.37
TYK2 P29597 6/20 0.36
THRB P10828 1/20 0.33
PTGS2 P35354 3/20 0.33
GPR119 Q8TDV5 3/20 0.33
PTGS1 P23219 2/20 0.32
CSNK1D P48730 2/20 0.31
MAPK14 Q16539 2/20 0.31
MAPK9 P45984 1/20 0.31
MAPK10 P53779 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6721680 0.91 PTGS2 (0.42) TYK2PTGS2PTGS1
SCHEMBL6718593 0.88 PTGS2 (0.45) PIK3CDPIK3CAPIK3CBPIK3CGTHRB
SCHEMBL6738961 0.87 TYK2 (0.33) TYK2PTGS2
SCHEMBL6725661 0.84 PTGS2 (0.38) PIK3CDPIK3CAPIK3CBPIK3CGTYK2
SCHEMBL6723177 0.84 PIK3CD (0.37) PIK3CDPIK3CAPIK3CBPIK3CGTYK2
SCHEMBL6721334 0.84 PTGS2 (0.47) PIK3CDPIK3CAPIK3CBPIK3CGTHRB
SCHEMBL6726075 0.83 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPIK3CGTHRB
SCHEMBL6722731 0.82 PTGS2 (0.42) PIK3CDPIK3CAPIK3CBPIK3CGPTGS2
SCHEMBL6734627 0.82 CA1 (0.37) PTGS2
SCHEMBL6722938 0.81 PTGS2 (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PIK3CD 4290/4885PIK3CA 3770/4885PIK3CB 2965/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PIK3CD 4382/4885PIK3CA 3934/4885PIK3CB 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.